Hypothesis: An attempt to explain the neurological symptoms of ME/CFS

An attempt to explain the neurological symptoms of Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome, by Klaus J Wirth, Carmen Scheibenbogen & Friedemann Paul in Journal of Translational Medicine volume 19, no: 471 (2021)

 

Review abstract

There is accumulating evidence of endothelial dysfunction, muscle and cerebral hypoperfusion in Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS).

In this paper we deduce the pathomechanisms resulting in central nervous pathology and the myriad of neurocognitive symptoms. We outline tentative mechanisms of impaired cerebral blood flow, increase in intracranial pressure and central adrenergic hyperactivity and how they can well explain the key symptoms of cognitive impairment, brain fog, headache, hypersensitivity, sleep disturbances and dysautonomia.

Excerpt from Introduction

Key neurological pathomechanisms in ME/CFS

ME/CFS is classified as a neurological disease. This is based on neurological symptoms including mental fatigue, impaired cognition, psychomotor slowing, disturbed sleep, hypersensitivities to noise, light and smells, headache, pain and paresthesias and severe dysautonomia.

Many symptoms are, however, not obviously explained by neurological pathology including the cardiovascular situation with orthostatic intolerance, hypovolemia and a low activity of the renin–angiotensin–aldosterone system (RAAS), or the impaired muscle function (reduced handgrip strength and fatigability) and energetic disturbance. This co-occurrence of seemingly unrelated symptoms and findings prompts to look for a unifying explanation (the most parsimonious explanation).

 The authors discuss:

  • Decreased cerebral blood flow (CBF)
  • Disturbed local blood flow regulation and neurovascular coupling
  • Increase in intracranial pressure
  • Disturbances of reflexes and autonomic function, hypervigilance and hypersensitivity to sensory stimuli such as light, noises and smells and brain fog
  • Hypocapnia, hyperventilation, respiratory alkalosis and possible consequences for skeletal muscle metabolism
  • Sleep disturbances and non-restorative sleep

Conclusion

Neurological symptoms in ME/CFS can be severe and debilitiating, but no clear specific brain pathology or lesions have been detected so far. Whether neuroinflammation or a brain stem pathology exists—where dysautonomia may have its origin as the primary disturbance eliciting ME/CFS—remains to be shown.

Decreased CBF, disturbed local blood flow regulation and neurovascular coupling, central adrenergic hyperactivity, hypocapnia and increase in intracranial presssure seem to play a strong role in the pathophysiology of the neurological symptoms in ME/CFS (Fig. 1). They can well explain cognitive impairment, brain fog, headache, psychomotor slowing, ataxia and loss of coordination of movements, hypersensitivity, sleep disturbances and dysautonomia.

Read full paper

Posted in News | Tagged , , , , , , , | Comments Off on Hypothesis: An attempt to explain the neurological symptoms of ME/CFS

Research: Understanding the molecular changes of PEM in ME/CFS

Understanding the molecular changes of Post Exertional Malaise in ME/CFS,  by Jemma Elley (Thesis, Bachelor of Biomedical Sciences with Honours). University of Otago, 2021

 

Research abstract:

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a debilitating and often life-long condition affecting over 20,000 New Zealanders. Symptoms include muscle and joint pain, severe fatigue, unrefreshing sleep, hypersensitivity to light and sound, and cognitive dysfunction. However, the condition lacks a reliable diagnostic biomarker, impairing patient diagnosis and treatment development. Previous research has identified several key physiological areas of promise from which markers might come, including mitochondrial dysfunction, HPA-axis impairment, immune alterations, increased oxidative stress and epigenome modifications.

This project focuses on post-exertional malaise (PEM), a cardinal symptom of ME/CFS. Post-exertional malaise is defined as an exacerbation of ME/CFS symptoms after physical, mental or emotional exertion. As PEM distinguishes ME/CFS from other fatigue-related conditions, it may aid in identifying the molecular basis of ME/CFS.

To determine the molecular changes leading to this malaise, five ME/CFS-affected individuals and two healthy controls performed an exercise paradigm where they were made to cycle on an ergometer until their peak work rate was reached. 20 mL of blood was taken from each individual before performing the exercise, and after two exercise episodes that were 24 hours apart.

Peripheral blood mononuclear cells (PBMCs) were purified from the blood by centrifuging on Ficol gradients. The mitochondrial function was determined on live cells using the Seahorse XF Cell Mito Stress Test Kit. The genomic DNA was extracted from the PBMCs and 8-hydroxy 2 deoxyguanosine (a marker of oxidative stress) was determined using an 8-hydroxy 2 deoxyguanosine ELISA Kit. Methylome changes were detected in the DNA by digestion of the DNA and preparation of 40-220bp fragment libraries before performing Reduced Representation Bisulfite sequencing.

A decrease in the mitochondrial function after the first exercise was observed in all ME/CFS individuals and one control. Contrary to existing literature, the ME/CFS group had, on average, a lower level of 8-hydroxy 2 deoxyguanosine compared to healthy controls.

An average of 1.25% of DNA fragments were differentially methylated between the baseline 24-hour and baseline and 48-hour samples. Results of a STRING protein network analysis on the differentially methylated fragments present in the promoter show interaction between upregulated mitochondrial, nervous system, immune function, and HPA-axis -associated genes. Additionally, hypermethylation and potentially decreased expression of POU3F4, a transcription factor with high expression levels in the basal ganglia (which regulates motor activity and motivation) provides evidence of how the PEM symptoms of increased fatigue and perceived exertion may arise.

Whilst the molecular changes during PEM are varied and complex, these results contribute to the knowledge of the processes underlying the symptoms, and by proxy, the overall pathophysiology of ME/CFS.

Supervisor: Prof Warren Tate

4.6. Conclusions

In summary, changes were observed in the oxygen consumption rate of ME/CFS subjects, as well as evidence of a difference between ME/CFS patients and healthy controls. The similarity in OCR profiles between ME/CFS-affected individuals and an over-exerted control should be further explored, as it potentially links the “increased perceived exertion” hypothesis with a physiological output.

The statistically significant decrease of ATP production after exercise should also be explored, potentially explaining the fatigue ME/CFS sufferers experience.
8-OHdG levels, as a measure of oxidative stress, did not appear to have drastic changes during the exercise paradigm, nor between ME/CFS individuals and controls. However, the spread of 8-OHdG levels in ME/CFS and healthy individuals should be assessed, as we cannot conclude that this minor difference is not, in fact, significant enough to act as a biomarker for ME/CFS.

Finally, significant differences in the DNA methylation of one individual’s genome was observed throughout the exercise paradigm, especially in genes related to the HPA-axis and immune system, metabolism, and circadian rhythm.

These findings buttress those reported by many other research groups. Whilst many researchers have investigated ME/CFS by comparing it to controls, the investigation of its key symptom, PEM, is underdeveloped. Therefore, this thesis contributes to filling a major gap in the field.

Additionally, this study employs a “precision medicine” approach, using patients as their own controls. Because of the fatigue-induced limitations of those with ME/CFS in partaking in studies, genome-wide investigations employing thousands of participants are not possible. This project provides an alternative, which, with increased sharing of data and machine learning, may provide a better way to approach ME/CFS research and the study of chronic illnesses in general.

Posted in News | Tagged , , , , , , , , , , , , , , | Comments Off on Research: Understanding the molecular changes of PEM in ME/CFS

Research review: Immunoglobulin therapy for ME/CFS

Back to the Future? Immunoglobulin therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, by  Helen Brownlie and Nigel Speight in Healthcare 2021, 9(11), 1546; [doi.org/10.3390/healthcare9111546]   12 Nov 2021 (This article belongs to the Special Issue ME/CFS – the Severely and Very Severely Affected)

 

Review abstract:

The findings of controlled trials on use of intravenous immunoglobulin G (IV IgG) to treat myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) are generally viewed as representing mixed results. On detailed review, a clearer picture emerges, which suggests that the potential therapeutic value of this intervention has been underestimated.

Our analysis is consistent with the propositions that:

  1. IgG is highly effective for a proportion of patients with severe and well-characterised ME/CFS;
  2. responders can be predicted with a high degree of accuracy based on markers of immune dysfunction.

Rigorous steps were taken in the research trials to record adverse events, with transient symptom exacerbation commonly experienced in both intervention and placebo control groups, suggesting that this reflected the impact of participation on people with an illness characterised by post-exertional symptom exacerbation. Worsening of certain specific symptoms, notably headache, did occur more commonly with IgG and may have been concomitant to effective treatment, being associated with clinical improvement.

The findings emerging from this review are supported by clinical observations relating to treatment of patients with severe and very severe ME/CFS, for whom intramuscular and subcutaneous administration provide alternative options.

We conclude that:

  1. there is a strong case for this area of research to be revived;
  2. pending further research, clinicians would be justified in offering a course of IgG to selected ME/CFS patients at the more severe end of the spectrum.

As the majority of trial participants had experienced an acute viral or viral-like onset, we further suggest that IgG treatment may be pertinent to the care of some patients who remain ill following infection with SARS-CoV-2 virus.

Posted in News | Tagged , , , , , , , , | Comments Off on Research review: Immunoglobulin therapy for ME/CFS

Research: The characterization of IL-2 stimulation & treatment of TRPM3… in ME/CFS

Characterization of IL-2 stimulation and TRPM7 pharmacomodulation in NK Cell cytotoxicity and channel Co-Localization with PIP2 in Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome patients, by Stanley Du Preez , Natalie Eaton-Fitch, Helene Cabanas, Donald Staines and Sonya Marshall-Gradisnik in Int. J. Environ. Res. Public Health 2021, 18(22), 11879; [doi.org/10.3390/ijerph182211879] 12 Nov 2021  (This article belongs to the Special Issue Chronic Fatigue Syndrome: Medical, Nursing and Public Health Management)

 

Research abstract:

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex multisystemic disorder responsible for significant disability. Although a unifying etiology for ME/CFS is uncertain, impaired natural killer (NK) cell cytotoxicity represents a consistent and measurable feature of this disorder.

Research utilizing patient-derived NK cells has implicated dysregulated calcium (Ca2+) signaling, dysfunction of the phosphatidylinositol-4,5-bisphosphate (PIP2)-dependent cation channel, transient receptor potential melastatin (TRPM) 3, as well as altered surface expression patterns of TRPM3 and TRPM2 in the pathophysiology of ME/CFS.

TRPM7 is a related channel that is modulated by PIP2 and participates in Ca2+ signaling. Though TRPM7 is expressed on NK cells, the role of TRPM7 with IL-2 and intracellular signaling mechanisms in the NK cells of ME/CFS patients is unknown.

This study examined the effect of IL-2 stimulation and TRPM7 pharmacomodulation on NK cell cytotoxicity using flow cytometric assays as well as co-localization of TRPM7 with PIP2 and cortical actin using confocal microscopy in 17 ME/CFS patients and 17 age- and sex-matched healthy controls.

The outcomes of this investigation are preliminary and indicate that crosstalk between IL-2 and TRMP7 exists. A larger sample size to confirm these findings and characterization of TRPM7 in ME/CFS using other experimental modalities are warranted.

Posted in News | Tagged , , , , , , , , , , | Comments Off on Research: The characterization of IL-2 stimulation & treatment of TRPM3… in ME/CFS

mapMECFS: new opportunities for discovery for ME/CFS researchers

mapMECFS – an interactive data portal

… providing access to research results across many biological disciplines from studies that are focused on advancing our understanding of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS).

 

The mapMECFS website serves as the omics data sharing portal for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) research, created as part of the NIH funded ME/CFS Network.

This website enables researchers to gain a broader view of ME/CFS by:

  • Bringing together the data that researchers have collected across the multiple systems affected by ME/CFS
  • Providing a dynamic navigation portal to search across these domains
  • Facilitating the integration of complementary data types to offer a new, more complete picture of the disorder

Mission
Our mission is to help ME/CFS researchers discover new insights about the disorder, promote data sharing between experts, and present a comprehensive picture of the hallmarks of this disorder. We hope these efforts help millions of people suffering from ME/CFS by enabling a faster path to better diagnostics and treatments.

Watch the video

mapMECFS: a portal to enhance data discovery across biological disciplines and collaborative sites

Posted in News | Tagged , | Comments Off on mapMECFS: new opportunities for discovery for ME/CFS researchers

World ME Alliance writes to WHO re long COVID definition

Will the World Health Organization’s long COVID definition help or hinder?

 

WAMES has joined other members of the World ME Alliance in writing to the World Health Organization (WHO) concerning their recently published definition of “post COVID-19 condition”, commonly known as long COVID.

 

While we commend the work undertaken to ensure people with long COVID are receiving a diagnostic label and subsequent support we remain concerned that a vague definition alone could hinder research and care efforts.

Further work, including stratification of sub-types is vital, and we call on the WHO to engage disease experts from areas such as ME in this.

 

Read our letter below:

Dear Dr Tedros Adhanom Ghebreyesus, Dr Ren Minghui and Dr Janet Diaz,

On 6th October, the World Health Organization published its definition of post COVID-19 condition (PCC).

Post COVID-19 condition occurs in individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis. Common symptoms include fatigue, shortness of breath, cognitive dysfunction but also others* and generally have an impact on everyday functioning. Symptoms may be new onset following initial recovery from an acute COVID-19 episode or persist from the initial illness. Symptoms may also fluctuate or relapse over time.

The undersigned organisations work for the benefit of people with myalgic encephalomyelitis (ME), a noncommunicable disease (NCD) with great experience of vague diagnostic definitions. There are now so many definitions of ME that research often isn’t comparable. Many of these definitions select such a broad population that research outcomes are considered of low or very low quality in systematic reviews. In fact, there is remarkable similarity between some of the definitions of ME and the recent definition of PCC published by the WHO.

We are concerned that this definition will lead to some of the same outcomes for people experiencing PCC as has happened for people with ME. Defined clinical pathways are clearly needed, and we commend the WHO on working towards this. However, now is the time to prioritise the categorisation of subtypes in order to expedite the delivery of appropriate treatment or management approaches for people presenting with different symptoms.

As research into this novel phenomenon develops, various phenotypes are being differentiated, and the WHO definition could emphasise this. (1) In particular, it is of vital importance that post-exertional malaise (PEM) is screened for, and where present people are supported to pace their energy levels within known limits (as per new guidance from the UK’s National Institute for Health and Care Excellence). (2) The findings of the Patient Led Research Collaborative, that “89.1% of participants reported experiencing either physical or mental PEM”, (3) affirm this.

There are many overlaps between the symptomology presenting in PCC and in ME. However, certain subgroups do not experience the symptoms of ME. We must now ensure that people diagnosed with PCC are appropriately sub-categorised, to ensure that we do delay the advancement of scientific understanding through:

  • misleading data and insignificant findings in research
  • inappropriate one-size-fits-all care

It is critical to identify and track the disease progressions of different subtypes, including those with ME, to identify risk and resiliency factors when compared to those who recover from COVID and healthy controls. As written, this definition alone will be harmful to critical research in the field.

We strongly encourage the WHO to work with NCD disease experts in related fields to develop guidance for clinical care and researchers that enables screening and tracking of ME and other conditions related to PCC, and fully defines the subgroups and their differentiating/differential symptoms.

The WHO has an opportunity here to make a difference for people with PCC, those with ME, and other NCDs who for many years have been out of the spotlight and largely ignored.

We therefore urge you to work with ME organisations and disease experts to make a statement on the similarities between PCC and ME, and the necessary differences in management approach for those experiencing post-exertional malaise.

Secondly, we urge you to ensure ME organisations and disease experts are central to future efforts to develop clinical care and research into PCC.

And finally, we urge the WHO to initiate education and research into PEM, as it remains such a misunderstood and highly disabling characteristic.

With regards,

Sonya Chowdhury,
Chair of the World ME Alliance

On behalf of the World ME Alliance members:

Action for M.E.
ACAF – Associació Catalana d’Afectades i Afectats de Fibromiàlgia i d’altres Síndromes de Sensibilització Central
AMMES – The American ME and CFS Society
ANZMES – The Associated New Zealand Myalgic Encephalomyelitis Society
AQEM – Association québécoise de l’encéphalomyélite myalgique
Forward M.E.
#MEAction
Plataforma Familiars FM-SFC-SQM Síndromes de Sensibilització Central
Solve M.E.
The ME CFS Foundation South Africa
WAMES – Welsh Association of ME & CFS Support

 

(1) Estiri, Hossein, Zachary H. Strasser, Gabriel A. Brat, Yevgeniy R. Semenov, Chirag J. Patel, and Shawn N. Murphy. “Evolving Phenotypes of non-hospitalized Patients that Indicate Long Covid.” medRxiv (2021).

(2) NICE. “Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management” Available at https://www.nice.org.uk/guidance/ng206 (2021)

(3) Davis, Hannah E., Gina S. Assaf, Lisa McCorkell, Hannah Wei, Ryan J. Low, Yochai Re’em, Signe Redfield, Jared P. Austin, and Athena Akrami. “Characterizing long COVID in an international cohort: 7 months of symptoms and their impact.” Available at SSRN 3820561 (2021).

Posted in News | Tagged , , , , | 1 Comment

Research review: Pain-related post-exertional malaise in ME/CFS & FM

Pain-related post-exertional malaise in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Fibromyalgia: a systematic review and three-level meta-analysis, by Ellen E Barhorst, Alex E Boruch, Dane B Cook in Pain Medicine, October 2021 [DOI:10.1093/pm/pnab308]

 

Review abstract:

Objective:

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Fibromyalgia (FM) are two debilitating, moderately comorbid illnesses in which chronic musculoskeletal pain symptoms are prevalent. These individuals can experience post-exertional malaise (PEM), a phenomenon where symptom severity is worsened 24hr or longer following physical stress, but the pain-related component of PEM is not well characterized.

Design:

Systematic review and meta-analysis.

Methods:

Case-control studies involving adults with ME/CFS or FM and measuring pain symptoms before and after exposure to a standardized aerobic exercise test were included. Hedges’ d effect sizes were aggregated using random effects models and potential moderators were explored with meta-regression analysis. Results were adjusted for nesting effects using three-level modeling.

Results:

Forty-five effects were extracted from 15 studies involving 306 patients and 292 healthy controls. After adjusting for nesting effects, we observed a small-to-moderate effect indicating higher post-exercise pain in patients than controls (Hedges’ d=0.42; 95% CI: 0.16, 0.67). The mean effect was significantly moderated by pain measurement timepoint (b = -0.19, z = -2.57, P = 0.01) such that studies measuring pain 8-72hr post-exercise showed larger effects (d = 0.71, 95% CI = 0.28-1.14) than those measuring pain 0-2hr post-exercise (d = 0.32, 95% CI = 0.10-0.53).

Conclusions:

People with ME/CFS and FM experience small-to-moderate increases in pain severity following exercise which confirms pain as a component of PEM and emphasizes its debilitating impact in ME/CFS and FM. Future directions include determining mechanisms of pain-related PEM and developing exercise prescriptions that minimize symptom exacerbation in these illnesses.

Posted in News | Tagged , , , , , , , , , | Comments Off on Research review: Pain-related post-exertional malaise in ME/CFS & FM

Diagnostic test research: Saliva fatigue biomarker for severe ME/CFS

Saliva fatigue biomarker index as a marker for severe myalgic encephalomyelitis/ chronic fatigue syndrome in a community based sample, by Leonard A Jason, John Kalns, Alicia Richarte, Ben Z Katz, Chelsea Torres in Fatigue: Biomedicine, Health & Behavior, October 27, 2021 [doi/full/10.1080/21641846.2021.1994222]

 

Research abstract:

Objective

The prevalence of pediatric Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS) has been estimated from an ethnically and sociodemographically diverse community-based random sample of 10,119 youth aged 5-17. We assessed whether a salivary biomarker of fatigue could identify youth with ME/CFS.

Study design

We examined the ratio of the concentrations of 2 peptide fragments in saliva, referred to as the Fatigue Biomarker Index (FBI), in participants from our study diagnosed with ME/CFS (n=59) and matched controls (n=39).

Results

Significant overall differences were found in the FBI between those participants with severe ME/CFS and those with ME/CFS and the controls.

Conclusions

If confirmed in other populations, the FBI could serve as an objective test to aid in the diagnosis of severe ME/CFS.

Full article behind a paywall

Posted in News | Tagged , , , , , , , | Comments Off on Diagnostic test research: Saliva fatigue biomarker for severe ME/CFS

Implement NICE ME/CFS guideline for safe, empathetic & equitable healthcare

WAMES asks NHS Wales:  Don’t delay!

Implement NICE ME/CFS guideline
for safe, empathetic & equitable healthcare

 

Poor healthcare for many with ME/CFS in Wales

A new WAMES report into the implementation in Wales of the 2007 NICE guideline illustrates how:

  • few GPs admit being aware of the guidelines and those who do, are often selective in what they implement
  • many GPs failed to accept that ME is a real, debilitating condition
  • it is difficult to find GPs who feel confident enough to diagnose
  • many GPs show patients with suspected ME little ‘respect, sensitivity and
    understanding’
  • very few GPs are able or willing to give patients information about the illness, its management and the possibility of relapses, or help them develop a care plan
  • there is no accepted management pathway – even if  there are specialist teams offering management advice or GET & CBT in an area, GPs often don’t know they can refer patients to them

“I spoke to him about latest research about a connection to autoimmune and he said we’ve done blood tests so you are fine. He said ‘we use NICE and I need to refer you to the psychology team’. He didn’t offer any more help than that.”

Earlier this year, before the publication of the revised NICE guideline for ME/CFS was delayed, WAMES asked people in Wales to tell us about their GP consultations. The response was low but we were grateful to the people who made the effort to share their experiences.

“Following routine bloods, I was called into surgery because of slight weight gain – new GP was confused about ME/CFS, used Internet to come up with GET, had no grasp of what that was, nor any understanding that the NICE Guidelines were under review. Whole thing was a tick box exercise, a wasted GP appointment and no help whatsoever to me.”

It was disappointing to hear the same kind of stories we have been hearing for decades. Patients often count themselves fortunate if a GP admits they have no knowledge, but are still concerned enough to spend time looking for something to help relieve their symptoms!

“The doctors… have poor understanding of the condition, especially the GPs, which of course then filters through to the rest of the practice. Not even a basic level of care, and crass remarks. I visit them as little as possible as it upsets me too much. This very much adds to a sense of isolation, hopelessness and being forgotten about.”

NICE also received  many examples of poor care and harm from treatments 

The WAMES report also explores the wide range of examples of poor healthcare that the NICE guideline committee received during the revision process. These include:

  • a lack of belief about ME/CFS as a real condition
  • a lack of understanding about what it is and the disabling impact it has, especially for the severely affected, including its fluctuating nature
  • confusing symptoms with signs of abuse or neglect, especially in children or the severely affected
  • difficulties accessing services due to distance, mobility, sensory overload etc
  • post code lottery for specialist services
  • harm reported from unstructured physical activity and inflexible exercise therapy designed to treat deconditioning

The new guideline is a ‘triumph of science over discrimination’.

Patients, and many doctors, researchers and physiotherapists have been vocal in welcoming the new guideline, which has a much improved definition of ME/CFS, a rejection of harmful inflexible therapies (GET & CBT) based on a theory of ‘deconditioning’ and ‘unhelpful illness beliefs’, a focus on energy management to avoid exacerbation of  symptoms (PEM).

There is a real opportunity for the 2021 NICE guideline to end the ‘health and social care crisis‘ for people with ME/CFS in Wales.

WAMES is therefore asking the NHS and health professionals in Wales not to delay any longer:

  • follow the science
  • listen to patients and carers
  • begin the process of developing a safe, empathetic and equitable healthcare service for people with ME/CFS
  • no delay – begin to implement the 2021 NICE ME/CFS guideline today!

Download the report: Is NICE ME/CFS guidance implemented in Wales?

Posted in News | Tagged , | 1 Comment

NICE ME/CFS guideline – doctors’ leaders reject ‘evidence based’ change

NICE 2021 ME/CFS guideline – 

Doctors’ leaders reject ‘evidence based’ change, but many believe the guideline can be transformative

 

On the whole patients are relieved that the revised NICE guideline for ME/CFS has at last been published and are pleased with the change in direction it has taken i.e. that Post Exertional Malaise (PEM) is now a defining characteristic, and that Graded Exercise Therapy (GET) & Cognitive Behavioural Therapy (CBT) are no longer seen as curative treatments, with GET being recognised as having caused harm to patients. Some doctors, health professionals and researchers on the other hand have been vehement in their opposition to the changes.

NICE took unprecedented steps to accommodate health professionals who had difficulties with the final version of the guideline by: delaying publication; listening to their concerns in a ‘Roundtable’ discussion; and altering some of the language in the final guideline.

Medical leaders’ joint statement

dr with stop signThis was not enough to appease them and following publication of the guideline a number of major UK medical organisations issued a scathing joint statement showing their lack of support for the guideline. The co-signatories of the statement represent thousands of medical personnel (though they were not consulted about the statement) and many CFS services that practise the discredited and now outlawed therapies of GET and CBT as treatments for ME/CFS.

The organisations opposed to the guideline are: Royal College of Physicians; Royal College of Physicians of Edinburgh; Royal College of General Practitioners; Royal College of Psychiatrists; Academy of Medical Royal Colleges; Faculty of Sport and Exercise Med

Their statement emphasises their belief that:

  • activity and exercise are important in the management of ME/CFS i.e. personalised paced exercise programmes
  • the phrase GET is unhelpful and this terminology should be dropped
  • there is a  connection between people’s mental and physical health – CBT remains a valuable treatment for alleviating symptoms in ME/CFS
  • specialist rehabilitation medicine services and exercise medicine services should be able to provide services for people with ME/CFS
  • the data and evidence had not been assessed correctly

They did not however produce any additional evidence at the Roundtable to support their claims and counteract the evidence underpinning the revised guideline. This was probably the reason their views did not alter the recommendations.

Expert comments

A number of researchers and doctors have been reported in the media to say the evidence supports GET and CBT as treatments, some of the statements coming from the Science Media Centre. Three of the eight professionals giving expert comment on the new guideline for the SMC are unwilling to accept the new narrower definition of ME/CFS or that there is evidence GET can cause harm.

“Researchers from different Institutions in different countries have found graded exercise therapy and cognitive behaviour therapy to be effective for some patients with CFS.  Evidence has shown they reduce fatigue and improve functioning without harm, if delivered by trained therapists in specialist clinics. “  Prof Trudie Chalder

The other five professionals writing for the SMC however supported the guideline and believed it was evidence based and could improve care for people with ME/CFS: Caroline Kingdon; Prof Chris Ponting; Dr David Strain; Dr Karl Morten; Prof Kevin McConway.

“This is a transformative step for treatments offered to ME/CFS patients in the UK.  I am hopeful that the move away from graded exercise to supporting patients in how they manage their daily activities will lead to more patients entering a recovery phase.  It is important that the appropriate support from clinicians and healthcare professionals be put in place and this a key component of  the new guidelines.” Dr Karl Morten

“The new NICE guidelines will improve the lives of people with ME worldwide, well beyond England and Wales.  They will improve awareness that graded exercise often makes ME symptoms worse.  NICE took due care and attention developing these guidelines, applying their rigorous methods and listening to highly regarded professionals and lay people.  Low and very low quality scientific evidence was rightly discarded.  Graded exercise therapy and cognitive behavioural therapy cannot now be offered as cures.  The new guidelines vindicate the longstanding views of many people with ME, their carers and families.”  Prof Chris Ponting

Applied statistics professor Kevin McConway examined the criticisms of NICE’s method of evaluating evidence and research, called GRADE, and explained on the SMC site that NICE had found numerous studies on illness definitions and treatments but concluded that many had “Very serious limitations” or “Serious limitations”. Based on the best evidence they could find they decided that GET and CBT were not safe curative treatments for a particular group of patients (those with PEM).  They were unable to find evidence for a cure but stated that more research was needed to uncover whether this was the best definition of ME/CFS and what treatments were suitable for the condition.

“Of course, it would be really good news if there were a cure, of whatever sort, but the new guideline makes it very clear indeed that “ME/CFS symptoms can be managed but there is currently no cure (non-pharmacological or pharmacological) for ME/CFS.”   Prof Kevin McConway

A Triumph of Science over Discrimination 

Doctors leaders might be resisting the new guideline but but the campaign group Doctors with M.E. calls it a ‘triumph of science over discrimination’.

“Doctors with M.E. considers the launch of this guideline to be a watershed moment in the history of ME/CFS medical care in the UK, with implications that extend to those Long Covid (PASC) patients who also meet ME/CFS diagnostic criteria.”

Physiotherapists embrace change

Physiotherapists have been at the forefront of services using GET with people with CFS. Now the Chartered Society for Physiotherapists(CSP) has come out in support of the guideline:

” I expect all those physiotherapists working with people who have ME/CFS to read the document, reflect on what this means for their practice and make any changes to their practice in light of the revised guidelines.” Natalie Beswetherick, director CSP

The professional group Physios for ME have been active in researching care for patients with PEM and educating colleagues about ‘the known adverse physiological effects of exertion.’ They welcome the guideline.

The over-riding message for physiotherapists is:
“Do not offer people with ME/CFS physical activity or exercise programmes that use fixed incremental increases, based on deconditioning and exercise avoidance theories as perpetuating ME/CFS.”

They do have some concerns about how it will be implemented, believing the information is not just for practitioners specialising in treating people with ME/CFS.

“We feel that education for all physiotherapists needs to be improved regarding ME, in particular the ability to identify and manage post exertional malaise, so that all physiotherapy interventions can be adapted and made suitable for a person with ME.”

Is widespread support for the Guideline possible?

In delaying publication and organising a Roundtable discussion NICE had hoped to secure widespread support for the guideline and was pleased enough with how the discussions had gone to announce:

“We are now confident that the guideline can be effectively implemented across the system and we will discuss the input from the meeting at our Guidance Executive next week with a view to publication of the guideline.”

NICE must have been as disappointed as anyone that the Colleges continued to reject both the evidence base for the guideline and the warning that ‘any programme based on fixed incremental increases in physical activity or exercise, for example graded exercise therapy (GET), should not be offered for the treatment of ME/CFS’. Some commentators have cast doubt on the critics’ ability to recognise scientific evidence:

“As has been widely reported, no substantive concerns were raised at the roundtable. Instead, the Colleges chose to release a controversial joint statement criticising NICE after the guideline was published. It is somewhat peculiar that a group of self-styled “medical leaders” should claim to champion science-based medicine, while simultaneously lobbying NICE to allow patients to be treated using such practices as the Lightning Process.” Prof Brian Hughes quotes the colleges submissions to NICE re the draft guideline.

Prof Tuller has noted that GET researchers have relied on re-affirming the soundness of their own research, without clear evidence, as a strategy which has worked for many years to deflect, discredit and/or squelch legitimate criticism!

Maybe now is the time for the critics to ‘get over themselves’!

Maybe now is the time for the critics to ‘get over themselves’! Yes, it must be disappointing to have exerted so much time and effort ‘backing the wrong horse’ but if they are right and their graded exercise/ activity approach can help some people, then they need to do some work and prove, with high quality research, who those people are. Many in the ME community would say a separation between ME and CFS is long overdue. People with Post-Exertional Malaise would be only too grateful if exercise therapy enthusiasts would direct their attention elsewhere for a change!

Links to health related articles

Association of Paediatric Chartered Physiotherapists (APCP): NICE ME/CFS guideline outlines steps for better diagnosis and management

BMJ: ME/CFS: Exercise goals should be set by patients and not driven by treatment plan, says NICE

(Includes responses from doctors & researchers urging doctors to take the scientific evidence base seriously)

Nursing Times: Updated ME/CFS guidance finally published following controversy

“This severe, complex multisystem disease has long been misjudged by the healthcare profession. Educating nurses about the needs of people with ME/CFS will help drive the step change in understanding and belief, compassion and empathy required to care for all patients with ME/CFS.” Caroline Kingdon, research nurse

Pulse: Final ME/CFS NICE guideline recommends ‘personalised care and support plan’  

GPonline: Reworked NICE advice on ME/CFS warns against ‘one-size-fits-all’ approach

Medscape: NICE publishes delayed ME/CFS guidance after summer controversy 

NHE: Intense exercise therapy for ME sufferers abolished

BACME: BACME welcomes the new NICE Guidance on ME/CFS

Pharmacy Magazine: NICE publishes delayed guideline on ME/CFS

Pharmacy business: NICE myalgic encephalomyelitis guidance lists better diagnosis and management methods

Virology blog: Trial by error: Losers in NICE guideline fight remain defiant despite public repudiation of their claims

 

See also the reactions of the ME community: 

NICE ME/CFS guideline – Cautious welcome from WAMES & the ME community

Posted in News | Tagged | Comments Off on NICE ME/CFS guideline – doctors’ leaders reject ‘evidence based’ change